首页> 中文期刊> 《中国实验血液学杂志》 >整合素蛋白连接激酶和蛋白激酶B在急性白血病中的表达及意义

整合素蛋白连接激酶和蛋白激酶B在急性白血病中的表达及意义

         

摘要

本研究探讨整合素蛋白连接激酶(ILK)和蛋白激酶B(PKB/Akt)在不同类型和疾病阶段的急性白血病(AL)患者中的表达,研究ILK/Akt通路在AL发病中的可能作用.应用RT-PCR法检测不同类型初治、复发及完全缓解AL患者和正常对照者骨髓单个核细胞中ILK mRNA和Akt mRNA的表达.结果表明,ILK和Akt在初治AL患者中的表达高于完全缓解组和正常对照组(P<0.05),在初治组与复发组中的表达差异无统计学意义(P>0.05).ILK和Akt的表达在AL中呈正相关性.结论:ILK和Akt在AL中异常高表达,而ILK/Akt信号通路可能参与了AL的发生发展,有可能成为AL治疗的新靶点.%The aim of this study was to investigate the expression of integrin linked kinase (ILK) and protein kinase B (PKB/Akt) in acute leukemia (AL), explore the possible effects of ILK/Akt pathway on AL pathogenesis. The expression level of ILK mRNA and Akt mRNA in different types and stages of AL bone marrow mononuclear cells was detected by reverse transcription polymerase chain reaction (RT-PCR). The results showed that the expression of ILK and Akt in do nove AL group was higher than that in AL-CR group and normal control group (P < 0. 05), while there was no statistically difference between de nove AL and relapsed AL groups( P >0.05). The expression of ILK positively correlates with Akt expression in de nove AL group (P < 0.05). It is concluded that the expression of ILK and Akt mRNA is abnormally higher in AL, ILK/Akt pathway may be involved in the pathogenesis and progression of AL and may be a potential therapeutic target for AL.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号